



an Open Access Journal by MDPI

Molecular Research of Glioblastoma

Guest Editors:

Dr. Esperanza R. Matarredona

Departamento de Fisiología,
Facultad de Biología,
Universidad de Sevilla, Seville,
Spain

Dr. Ricardo Gargini

Neurooncology Unit, Instituto de
Salud Carlos III-UFIEC, 28220
Madrid, Spain

Deadline for manuscript
submissions:
closed (31 October 2022)

Message from the Guest Editors

The molecular biology of human glioblastoma, the most aggressive primary brain tumor, is a fast-progressing field in which basic research needs to meet clinical expectations in terms of anti-tumor efficacy. Therefore, a deeper knowledge of the connection between the bio-molecular and clinical features of this disease is needed in order to develop new treatments. These include signal transduction pathways involved in glioma formation and progression, energy metabolism requirements, interactions between glioma cells and their microenvironment (immune cells, blood vessels, or neurons/glial cells), as well as signaling mechanisms involved in these interactions.

This Special Issue aims to present a collection of original research and review articles dealing with different aspects of the molecular biology and clinical features of glioblastoma, with the hope of shedding some light on the pathological mechanisms of this devastating tumor that may help to improve treatment strategies for patients with this disease.



mdpi.com/si/76161



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI